Curated News
By: NewsRamp Editorial Staff
May 29, 2026

Optimi Health Backs Australia's Expanded Psychedelic Therapy Rules

View History of this news story on GitHub
Original Source

TLDR

  • Optimi Health gains first-mover advantage as Australia expands psilocybin and MDMA prescribing, unlocking new market opportunities.
  • Australia’s TGA revised framework broadens therapy teams and settings, enabling scalable psychedelic-assisted treatment with Optimi’s GMP-compliant drugs.
  • Expanded access to psychedelic therapy in Australia offers hope for PTSD and depression patients, especially in rural areas.
  • No serious adverse events reported in Australia’s regulated psychedelic program since December 2025, supporting safety and expansion.

Impact - Why it Matters

This news matters because Australia's updated Authorized Prescriber scheme for psilocybin and MDMA could set a global precedent for regulated psychedelic-assisted therapy. By broadening treatment settings and workforce capacity, the framework aims to make these therapies more accessible, especially in rural areas. For patients with PTSD or treatment-resistant depression, this means potentially life-changing treatments could become more widely available. The absence of serious adverse events since December 2025 further supports the safety and viability of these therapies, encouraging other nations to consider similar regulatory paths. Investors and healthcare providers should watch this development as it signals growing acceptance and commercialization of psychedelic medicine.

Summary

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a leading commercial-stage psychedelic pharmaceutical manufacturer, has welcomed final recommendations from Australia’s Therapeutic Goods Administration (TGA) regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments, and supports scaling of psychedelic-assisted therapy across Australia. Under this scheme, authorized psychiatrists can prescribe Optimi’s GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression, marking a significant step forward in mental health treatment accessibility.

Optimi Health said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. The company also noted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies. This safety record reinforces confidence in the regulated use of these substances for therapeutic purposes.

Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. The company is positioned to benefit from Australia’s progressive regulatory environment, which could serve as a model for other countries considering similar frameworks. For more details, visit the full press release at https://nnw.fm/yYW7j. This news was disseminated by NetworkNewsWire, a platform within the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Optimi Health Backs Australia's Expanded Psychedelic Therapy Rules

blockchain registration record for this content.